| http://www.w3.org/ns/prov#value | - We have stayed out of the renal cell arena, because it is crowded, its complex, not because we do not think deforolimus will work there, because we do, but we have, I think, bigger opportunities first-in-class in best-in-class opportunities in sarcoma, in breast and other malignancies and he is what we are pursuing as part of our joint program with Merck.
|
